BIOMAT Database Logo BIOMAT Database Logo

Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines. 2010

Junghun Lee, and Hwan Kim, and Hana Yu, and Jae Yoon Chung, and Chang-Hyun Oh, and Kyung Ho Yoo, and Taebo Sim, and Jung-Mi Hah
Life/Health Division, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea.

The synthesis of a novel series of pyrimidin-4-yl-1H-imidazol-2-yl derivatives 7, 8, 9 and their antiproliferative activities against A375P human melanoma cell line and WM3629 cell line were described. Most compounds showed superior antiproliferative activities compared to Sorafenib, the well-known RAF inhibitor. Among them, 7a exhibited potent activities on both cell lines (IC(50)=0.62 and 4.49muM, respectively) and turned out to be a selective and potent CRAF inhibitor.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D009536 Niacinamide An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. Nicotinamide,Vitamin B 3,Vitamin PP,3-Pyridinecarboxamide,Enduramide,Nicobion,Nicotinsäureamid Jenapharm,Papulex,Vitamin B3,3 Pyridinecarboxamide,B 3, Vitamin,B3, Vitamin,Jenapharm, Nicotinsäureamid
D010671 Phenylurea Compounds Compounds that include the amino-N-phenylamide structure. Phenylcarbamides,Phenylurea Derivatives,Compounds, Phenylurea,Derivatives, Phenylurea
D011494 Protein Kinases A family of enzymes that catalyze the conversion of ATP and a protein to ADP and a phosphoprotein. Protein Kinase,Kinase, Protein,Kinases, Protein
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077157 Sorafenib A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy. 4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate,BAY 43-9006,BAY 545-9085,BAY-545-9085,BAY-673472,Nexavar,Sorafenib N-Oxide,Sorafenib Tosylate,BAY 43 9006,BAY 439006,BAY 545 9085,BAY 5459085,BAY 673472,BAY5459085,Sorafenib N Oxide
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

Junghun Lee, and Hwan Kim, and Hana Yu, and Jae Yoon Chung, and Chang-Hyun Oh, and Kyung Ho Yoo, and Taebo Sim, and Jung-Mi Hah
Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines.
August 2011, European journal of medicinal chemistry,
Junghun Lee, and Hwan Kim, and Hana Yu, and Jae Yoon Chung, and Chang-Hyun Oh, and Kyung Ho Yoo, and Taebo Sim, and Jung-Mi Hah
Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. Part 2.
July 2012, Bioorganic & medicinal chemistry letters,
Junghun Lee, and Hwan Kim, and Hana Yu, and Jae Yoon Chung, and Chang-Hyun Oh, and Kyung Ho Yoo, and Taebo Sim, and Jung-Mi Hah
4-[4-(1H-Imidazol-4-yl)phen-yl]-1H-imidazole.
September 2012, Acta crystallographica. Section E, Structure reports online,
Junghun Lee, and Hwan Kim, and Hana Yu, and Jae Yoon Chung, and Chang-Hyun Oh, and Kyung Ho Yoo, and Taebo Sim, and Jung-Mi Hah
Synthesis and in vitro antiproliferative activity of 2-methyl-3-(2-piperazin-1-yl-ethyl)-pyrido[1,2-a]pyrimidin-4-one derivatives against human cancer cell lines.
January 2012, Archives of pharmacal research,
Junghun Lee, and Hwan Kim, and Hana Yu, and Jae Yoon Chung, and Chang-Hyun Oh, and Kyung Ho Yoo, and Taebo Sim, and Jung-Mi Hah
Synthesis of 1H-pyrazole-1-carboxamide derivatives and their antiproliferative activity against melanoma cell line.
March 2011, Archiv der Pharmazie,
Junghun Lee, and Hwan Kim, and Hana Yu, and Jae Yoon Chung, and Chang-Hyun Oh, and Kyung Ho Yoo, and Taebo Sim, and Jung-Mi Hah
Iodinated 4,4'-bipyridines with antiproliferative activity against melanoma cell lines.
March 2024, ChemMedChem,
Junghun Lee, and Hwan Kim, and Hana Yu, and Jae Yoon Chung, and Chang-Hyun Oh, and Kyung Ho Yoo, and Taebo Sim, and Jung-Mi Hah
Antifungal and antimycobacterial activity of 1-(3,5-diaryl-4,5-dihydro-1H-pyrazol-4-yl)-1H-imidazole derivatives.
April 2008, Bioorganic & medicinal chemistry,
Junghun Lee, and Hwan Kim, and Hana Yu, and Jae Yoon Chung, and Chang-Hyun Oh, and Kyung Ho Yoo, and Taebo Sim, and Jung-Mi Hah
Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
January 2019, Medicinal chemistry (Shariqah (United Arab Emirates)),
Junghun Lee, and Hwan Kim, and Hana Yu, and Jae Yoon Chung, and Chang-Hyun Oh, and Kyung Ho Yoo, and Taebo Sim, and Jung-Mi Hah
Discovery of Novel 2-(piperidin-4-yl)-1H-benzo[d]imidazole Derivatives as Potential Anti-Inflammatory Agents.
October 2015, Chemical biology & drug design,
Junghun Lee, and Hwan Kim, and Hana Yu, and Jae Yoon Chung, and Chang-Hyun Oh, and Kyung Ho Yoo, and Taebo Sim, and Jung-Mi Hah
Imidazole-4,5-dicarboxamide derivatives with antiproliferative activity against HL-60 cells.
September 2005, Journal of medicinal chemistry,
Copied contents to your clipboard!